XTX Topco Ltd Purchases Shares of 35,151 Annexon, Inc. (NASDAQ:ANNX)

XTX Topco Ltd bought a new position in Annexon, Inc. (NASDAQ:ANNX) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 35,151 shares of the company’s stock, valued at approximately $180,000.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Annexon by 11.6% during the 4th quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company’s stock worth $28,456,000 after purchasing an additional 576,625 shares during the period. Candriam S.C.A. raised its holdings in Annexon by 15.6% in the fourth quarter. Candriam S.C.A. now owns 2,534,230 shares of the company’s stock worth $13,001,000 after purchasing an additional 341,431 shares in the last quarter. Geode Capital Management LLC raised its holdings in Annexon by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 2,171,478 shares of the company’s stock worth $11,142,000 after purchasing an additional 27,843 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Annexon by 16.0% in the third quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock worth $10,101,000 after purchasing an additional 235,810 shares in the last quarter. Finally, Mutual of America Capital Management LLC raised its holdings in Annexon by 56.2% in the fourth quarter. Mutual of America Capital Management LLC now owns 1,029,680 shares of the company’s stock worth $5,282,000 after purchasing an additional 370,426 shares in the last quarter.

Annexon Stock Up 0.5 %

Shares of NASDAQ ANNX opened at $1.89 on Tuesday. The business’s 50 day moving average price is $2.15 and its 200 day moving average price is $4.18. The firm has a market cap of $207.35 million, a P/E ratio of -1.80 and a beta of 1.24. Annexon, Inc. has a 52 week low of $1.29 and a 52 week high of $7.85.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05). As a group, research analysts expect that Annexon, Inc. will post -0.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and set a $16.00 price objective on shares of Annexon in a report on Tuesday, March 4th.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.